Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Shares to Watch
The top 10 mid cap stocks to add to your watchlist
⏸️ Investing
The easy way to start building a $1 million share portfolio in FY 2017
⏸️ Investing
Is Cochlear Limited a Sell at today's share price?
⏸️ Investing
Macquarie Securities names list of reliable growth stocks
⏸️ Investing
Why the Australian dollar could fall to US 68 cents
⏸️ Investing
Could these 3 blue-chip businesses actually be cheap?
⏸️ Investing
The 'lazy way' to make a million dollar fortune
⏸️ Investing
5 top stocks for financial year 2017
⏸️ Investing
2 healthcare stocks that look better value than CSL Limited
⏸️ Investing
What investors should do now
⏸️ Investing
5 ASX shares to beat the Brexit sell off
⏸️ Investing
10 things I've learned from The Motley Fool Australia
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
